Jaime Modiano
Fondateur chez ApopLogic Pharmaceuticals, Inc.
Profil
Jaime F.
Modiano is the founder of ApopLogic Pharmaceuticals, Inc., which was founded in 2006.
He held the title of Scientist at the company.
Dr. Modiano's former job positions include being an Assistant Professor at Texas A&M University from 1995 to 1999, an Associate Professor at the University of Colorado Health Sciences Center in 2007, and a Senior Scientist at AMC Cancer Research Center.
Dr. Modiano's education history includes earning a doctorate degree from the University of Pennsylvania in 1991 and an undergraduate degree from El Colegio de México AC in 1981.
Postes actifs de Jaime Modiano
| Sociétés | Poste | Début |
|---|---|---|
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Fondateur | 01/08/2006 |
Anciens postes connus de Jaime Modiano
| Sociétés | Poste | Fin |
|---|---|---|
| University of Colorado Health Sciences Center | Corporate Officer/Principal | 01/01/2007 |
| Texas A&M University | Corporate Officer/Principal | 01/01/1999 |
| AMC Cancer Research Center | Corporate Officer/Principal | - |
Formation de Jaime Modiano
| El Colegio de México AC | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Health Technology |
| AMC Cancer Research Center |
